New antirheumatic drugs: Any real added value? A critical overview of regulatory criteria for their marketing approval
Bertele' V, Assisi A, Di Muzio V, Renzo D, Garattini S. New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval. Eur J Clin Pharmacol 2007;63:879-889.
Treatment of rheumatoid arthritis: New therapeutic approaches with biological agents
Afeltra A. Treatment of rheumatoid arthritis: new therapeutic approaches with biological agents. Curr Drug Targets Immune Endocr Metabol Disord 2001;1:45-65.
Open-label evaluation of the efcacy and safety of etanercept in rheumatoid arthritis
Misra R, Amin S, Joshi VR, Rao URK, Aggarwal A, Fatima F, et al. Open-label evaluation of the efcacy and safety of etanercept in rheumatoid arthritis. J Indian Rheumatol Assoc 2005; 13131-13134.
Antitumor necrosis factor-induced neutropenia: A case report with double positive rechallenges
epub 2006 oct 10
Montané E, Sallés M, barriocanal A, Riera E, Costa J, tena X. Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges. Clin Rheumatol 2007;26:1527-1529. epub 2006 oct 10.